PatSnap/clinical-trial huggingface dataset:
Clinical trial NCT02389751: Ganetespib in Combination With Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-III Esophageal Cancer
Official title: GUARDIAN-1 Trial: A Phase 1 Study of Ganetespib in Combination With Chemoradiation for Stage II-III Esophageal Carcinoma
Conditions: Gastroesophageal Junction Adenocarcinoma
Malignant Neoplasm of the Cervical Esophagus
Malignant Neoplasm of the Thoracic Esophagus
Stage IIA Esophageal Cancer AJCC v7
Stage IIB Esophageal Cancer AJCC v7
Stage IIIA Esophageal Cancer AJCC v7
Stage IIIB Esophageal Cancer AJCC v7
Stage IIIC Esophageal Cancer AJCC v7
Summary: This phase I trial studies the side effects and best dose of ganetespib when given together with paclitaxel, carboplatin, and radiation therapy in treating patients with stage II-III esophageal cancer. Ganetespib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving ganetespib in combination with paclitaxel, carboplatin, and radiation therapy may be a better treatment for patients with esophageal cancer.
Interventions:
description: Given IV
name: Carboplatin
other_name: Blastocarb
CBDCA
Carboplat
Carboplatin Hexal
Carboplatino
Carbosin
Carbosol
Carbotec
Displata
Ercar
JM-8
Nealorin
Novoplatinum
Paraplatin
Paraplatin AQ
Paraplatine
Platinwas
Ribocarbo
type: Drug
description: Given IV
name: Ganetespib
other_name: Hsp90 Inhibitor STA-9090
STA-9090
type: Drug
description: Given IV
name: Paclitaxel
other_name: Anzatax
Asotax
Bristaxol
Praxel
Taxol
Taxol Konzentrat
type: Drug
description: Undergo radiation therapy
name: Radiation Therapy
other_name: Cancer Radiotherapy
Irradiate
Irradiated
RADIOTHERAPY
RT
Radiation
Radiotherapeutics
Therapy, Radiation
irradiation
type: Radiation
Study arms:
design_group_description: Patients receive ganetespib IV over 1 hour, paclitaxel IV over 1 hour, and carboplatin IV over 30 minutes once a week on day 1. Patients also undergo radiation therapy 5 days a week for 5.5 weeks or for a total of 28 treatments. Treatment continues for 28 treatment days (5.5 weeks) in the absence of disease progression or unacceptable toxicity
design_group_title: Treatment (ganetespib, paclitaxel, carboplatin, radiation)
design_group_type: Experimental
Sponsor: The University of Texas MD Anderson Cancer Center
Collaborators: National Cancer Institute
Drug name mappings:
name: Ganetespib
lang: EN
name: 卡铂
lang: CN
name: Carboplatin
lang: EN
name: カルボプラチン
lang: JP
name: 紫杉醇
lang: CN
name: Paclitaxel
lang: EN
name: パクリタキセル
lang: JP
Clinical trial NCT06237205: Genome-Based Assessment of Niraparib (ZEJULA®) Efficacy in Advanced Solid TumorS With Homologous Recombination Deficiency
Official title: Genome-Based Assessment of Niraparib (ZEJULA®) Efficacy in Advanced Solid TumorS With Homologous Recombination Deficiency (GAUSS)
Conditions: Efficacy
Summary: Investigational Products: Niraparib Period: 3 years after IRB/EC approval Indication: Adult patients with histologically confirmed and locally advanced, unresectable, or metastatic solid tumors having known or suspected deleterious mutations in genes involved in homologous recombination repair (HRR) or homologous recombination deficiency identified by whole genome sequencing
Interventions:
description: a highly selective PARP1 and PARP2 inhibitor
name: Niraparib
type: Drug
Study arms:
design_group_title: Niraparib
design_group_type: Experimental
Sponsor: Korea University Anam Hospital
Collaborators: Takeda Pharmaceutical Co., Ltd.
Korean Cancer Study Group
Drug name mappings:
name: 甲苯磺酸尼拉帕利
lang: CN
name: Niraparib Tosylate
lang: EN
name: ニラパリブトシル酸塩水和物
lang: JP
Clinical trial NCT03489395: A Pilot Study on Edoxaban for the Resolution of Left Atrial Thrombosis in Patients With Non-valvular Atrial Fibrillation
Official title: A Pilot Study on Edoxaban for the Resolution of Left Atrial Thrombosis in Patients With Non-valvular Atrial Fibrillation
Conditions: Atrial Fibrillation
Summary: Isolated reports have indicated that complete Left Atrial or Left Atrial Appendage thrombus resolution may be achieved also with use of oral Factor Xa inhibitors, which have demonstrated the same efficacy but a better safety profile compared to warfarin.
The aim of this open-label pilot study is to investigate the percentage of Left Atrial /Left Atrial Appendage thrombus resolution with edoxaban therapy in patients with non-valvular atrial fibrillation. The subordinated aim is the design a larger and longer study to compare edoxaban and warfarin in the same patient population.
With the exception of few case reports, there are no data in the same patient population referred to antithrombotic treatments other than vitamin K antagonists.
Interventions:
description: Edoxaban 60 mg once a day for 4 weeks. Edoxaban 30 mg/day in patients with body weight ≤60 kg, or with concomitant therapy with verapamil/quinidine/dronedarone.
name: Edoxaban
other_name: Lixiana
type: Drug
Study arms:
design_group_description: Used for Treatment. All patients will receive edoxaban 60 mg once a day, with open-label design, for 4 weeks. Edoxaban daily dose will be reduced to 30 mg/day in case of: body weight ≤60 kg, or concomitant therapy with verapamil/quinidine/dronedarone.
design_group_title: Edoxaban
design_group_type: Experimental
Sponsor: University of Chieti-Pescara
Collaborators: Hippocrates Research
Drug name mappings:
name: 甲苯磺酸艾多沙班
lang: CN
name: Edoxaban Tosylate
lang: EN
name: エドキサバントシル酸塩水和物
lang: JP
Clinical trial NCT05900648: Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME)
Official title: Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME)
Conditions: Colorectal Cancer
Colon Cancer
Rectum Cancer
Summary: To measure the level of circulating tumor DNA (ctDNA) in the blood of colorectal cancer patients after 6 months of receiving therapy with regorafenib and XmAb20717 (also known as vudalimab). ctDNA is genetic material from tumor cells that can be found and measured in the blood
Interventions:
description: Given by PO
name: Regorafenib
other_name: BAY 73-4506
type: Drug
description: Given by (IV) vein
name: XmAb20717
type: Drug
Study arms:
design_group_description: Participants will receive regorafenib and XmAb20717 for up to 6 cycles (6 months). Participants will take regorafenib by mouth on Days 1-21 of each cycle. Participants will rest (not take regorafenib) on Days 21-28 of each cycle. Participants will also receive XmAb20717 by vein on Days 1 and 15 of each cycle. Each infusion should take about 60 minutes.
design_group_title: Regorafenib and XmAb20717
design_group_type: Experimental
Sponsor: The University of Texas MD Anderson Cancer Center
Collaborators: Xencor, Inc.
Bayer AG
Drug name mappings:
name: Vudalimab
lang: EN
name: 瑞戈非尼
lang: CN
name: Regorafenib
lang: EN
name: レゴラフェニブ水和物
lang: JP
Clinical trial NCT02445131: Sequential Regimen of Bendamustine-Debulking Followed by CAL-101 and GA101-Induction and -Maintenance in CLL (CLL2-BCG)
Official title: Prospective, Open-label, Multicenter Phase-II Trial to Evaluate Efficacy and Safety of a Sequential Regimen of Bendamustine Followed by GA101 (Obinutuzumab) and CAL-101 (Idelalisib) Followed by CAL-101 and GA101 Maintenance in CLL Patients
Conditions: Chronic Lymphocytic Leucemia
Summary: The CLL2-BCG-trial is a prospective, open-label, multicenter phase-II-trial to evaluate the efficacy and safety of a sequential regimen of a debulking with bendamustine followed by an induction with GA101 (obinutuzumab) and CAL-101 (idelalisib) followed by CAL-101 and GA101-maintenance in CLL patients
Interventions:
description: Debulking: Cycles 1 - 2, d1 & 2: 70 mg/m2 i.v.
name: Bendamustine
type: Drug
description: Induction: Cycle 1: d1: 100mg, d1(or2): 900mg, d8 & 15: 1000mg; Cycle 2-6: d1: 1000mg<br/>Maintenance: Cycle 1-8 (Duration 12 weeks): d1 1000 mg.
name: GA101
other_name: Obinutuzumab
type: Drug
description: Induction: Cycle 2-6: d1-28: 150 mg p.o.<br/>Maintenance: Cycles 1-8 (Duration 12 weeks): d1-84 150 mg p.o.
name: CAL-101
other_name: Idelalisib
type: Drug
Study arms:
design_group_description: Bendamustine: 70 mg/m2 i.v. GA101: 1000 mg CAL-101: 150 mg p.o.
design_group_title: Bendamustine + GA101 + CAL-101
design_group_type: Experimental
Sponsor: German CLL Study Group
Collaborators: Hoffmann-La Roche, Inc.
Gilead Sciences, Inc.
Drug name mappings:
name: 盐酸苯达莫司汀
lang: CN
name: Bendamustine Hydrochloride
lang: EN
name: ベンダムスチン塩酸塩
lang: JP
name: 艾德拉尼
lang: CN
name: Idelalisib
lang: EN
name: 奥妥珠单抗
lang: CN
name: Obinutuzumab
lang: EN
name: オビヌツズマブ（遺伝子組換え）
lang: JP
Clinical trial NCT04153487: Role of Ascorbic Acid Infusion in Critically Ill Patients With Transfusion Related Acute Lung Injury
Official title: Role of Ascorbic Acid Infusion in Critically Ill Patients With Transfusion Related Acute Lung Injury
Conditions: Acute Lung Injury, Transfusion Related
Summary: TRALI was defined as "acute noncardiogenic pulmonary edema typically occurs ≤ 6 hours following transfusion of plasma-containing blood products, such as packed red blood cells, fresh frozen plasma, platelets, or cryoprecipitate." In critically ill patients, TRALI remains the leading cause of transfusion-related fatalities and is accompanied by a very significant morbidity and mortality. Survival in such patients is as low as 53% compared with 83% in acute lung injury (ALI) controls.
The incidence of TRALi is likely underreported. In densely populated developing countries, incidence has not decreased due to lack of male-only strategy for plasma donation.
TRALI is associated with systemic inflammation characterized by low anti-inflammatory cytokine as interleukin (IL)-10, increased pro-inflammatory cytokine as IL-8. Regulation of inflammation should include avoidance of overproduction of inflammatory mediators. So, it can be dampened not only by increasing IL-10 but also by decreasing IL-1β release. C-reactive protein (CRP) is an acute phase protein which is up-regulated during infections and inflammation. CRP was recently identified as a novel first hit in TRALI.
Till now, there is no established treatment for TRALI beyond supportive care and monitoring. Recently, potential therapies have been reviewed, and it was concluded that the most promising therapeutic strategies are IL-10 therapy, downregulation of CRP levels, targeting reactive oxygen species (ROS) or blocking IL-8 receptors. So, antioxidants (such as high dose vitamins), were recommended for future studies as potentially effective treatment.
Vitamin C hypovitaminosis is observed in 70% of critically ill despite receiving recommended daily doses.
The aim of this study is to investigate the role of intravenous vitamin C (ascorbic acid) as a targeted therapy for transfusion related acute lung injury (TRALI) in critically ill patients in terms of IL-8, IL-10, CRP, SOD, malondialdehyde (MDA), vasopressor use, duration of mechanical ventilation, ICU length of stay, 7-days mortality and 28-days mortality.
Interventions:
description: Intermittent Intravenous Infusion of Ascorbic Acid (Vitamin C) 2.5 gm / 6 hours for 96 hours
name: Ascorbic Acid Injectable Product
other_name: Vitamin C
type: Drug
description: Placebo saline / 6 hours for 96 hours
name: Placebo
other_name: Normal saline
type: Drug
Study arms:
design_group_description: ASTRALI (AScorbic acid in TRALI) group (n=40)
design_group_title: ASTRALI Group
design_group_type: Experimental
design_group_description: Control group (n=40)
design_group_title: Control Group
design_group_type: Placebo Comparator
Sponsor: Damanhour University
Collaborators: Alexandria University
Drug name mappings:
name: 维生素C
lang: CN
name: Ascorbic Acid
lang: EN
name: アスコルビン酸
lang: JP
Clinical trial NCT06500273: Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Official title: A Randomized, Open-label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants With Minimal Residual Disease After Response to First Line Therapy for Large B-cell Lymphoma
Conditions: Large B-cell Lymphoma
Summary: This is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but who have minimal residual disease (MRD) as detected by the Foresight CLARITY™ Investigational Use Only (IUO) MRD test, powered by PhasED-Seq™. The purpose of the trial is to assess the efficacy and safety of consolidation with cemacabtagene ansegedleucel (cema-cel), an allogeneic CD19 CAR T product, as compared to standard of care observation.
In this study, participants with MRD are randomized 1:1 to treatment with cema-cel or an observation arm. Treatment includes cema-cel following a lymphodepletion regimen of fludarabine and cyclophosphamide.
Prior to August 2025, participants may also have received an anti-CD52 monoclonal antibody, ALLO-647, as part of their lymphodepletion regimen.
Interventions:
description: An allogeneic CAR T cell therapy targeting CD19
name: cemacabtagene ansegedleucel
other_name: cema-cel
type: Genetic
description: Chemotherapy for lymphodepletion
name: Fludarabine
other_name: Fludara®
type: Drug
description: Chemotherapy for lymphodepletion
name: Cyclophosphamide
other_name: Cytoxan®
type: Drug
description: A diagnostic test intended to identify patients with minimal residual disease at the end of first line treatment for LBCL.
name: Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™
other_name: Foresight Lymphoma MRD Therapy Selection Test
type: Device
Study arms:
design_group_description: Participants receive cemacabtagene ansegedleucel following lymphodepletion regimen comprised of fludarabine and cyclophosphamide.
design_group_title: cemacabtagene ansegedleucel
design_group_type: Experimental
design_group_description: Participants do not receive any study treatments. They are observed as per the current standard of care.
design_group_title: Observation
design_group_type: Other
Sponsor: Allogene Therapeutics, Inc.
Collaborators: Foresight Diagnostics, Inc.
Drug name mappings:
name: 磷酸氟达拉滨
lang: CN
name: Fludarabine Phosphate
lang: EN
name: フルダラビンリン酸エステル
lang: JP
name: 环磷酰胺
lang: CN
name: Cyclophosphamide
lang: EN
name: シクロホスファミド水和物
lang: JP
name: Cemacabtagene ansegedleucel
lang: EN
Clinical trial NCT03762161: A Phase II Study of Lonsurf (TAS-102) in Metastatic Platinum and Checkpoint Inhibitor-resistant Bladder Cancer
Official title: A Phase II Study of TAS-102 in Metastatic Platinum and Checkpoint Inhibitor-resistant Bladder Cancer
Conditions: Bladder Cancer
Summary: This study evaluates the clinical benefit of TAS-102 in participants with metastatic urothelial carcinoma who are resistant to cisplatin or carboplatin front-line and checkpoint inhibitors as second line therapy. All participants will receive TAS-102 in oral form twice per day on Days 1-5 and Days 8-12 of each 28 day cycle.
Interventions:
description: Participant self-administered orally at 35 milligrams per meter squared (mg/m2) twice daily Days 1-5 and 8-12 of every 28 day cycle
name: TAS 102
type: Drug
Study arms:
design_group_title: Intervention TAS-102
design_group_type: Experimental
Sponsor: University of Kansas Medical Center
Collaborators: Taiho Oncology, Inc.
Drug name mappings:
name: 曲氟尿苷替匹嘧啶
lang: CN
name: Tipiracil Hydrochloride/Trifluridine
lang: EN
name: トリフルリジン/チピラシル塩酸塩
lang: JP
Clinical trial NCT00955409: Long Term Extension Study Evaluating Safety, Tolerability and Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
Official title: A PHASE IIA, MULTICENTER, RANDOMIZED, THIRD-PARTY UNBLINDED, LONG -TERM EXTENSION STUDY TO DETERMINE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF ACC-001 WITH QS-21 ADJUVANT IN SUBJECTS WITH MILD TO MODERATE ALZHEIMER'S DISEASE
Conditions: Alzheimer Disease
Summary: The purpose of this study is to assess the long term safety, tolerability, and immunogenicity of ACC-001, an investigational active immunization product+, in subjects with mild to moderate Alzheimer's disease.
Interventions:
description: Vanutide Cridificar (ACC-001) 3µg + QS-21 (50µg), IM on Day 1, Month 6, Month 12 and Month 18
name: ACC-001(3µg) + QS21
type: Biological
description: Vanutide Cridificar (ACC-001) 10µg + QS-21 (50µg), IM on Day 1, Month 6, Month 12 and Month 18
name: ACC-001(10µg) + QS21
type: Biological
description: Vanutide Cridificar (ACC-001) 30 µg + QS-21 (50µg), IM on Day 1, Month 6, Month 12 and Month 18
name: ACC-001(30µg) + QS21
type: Biological
Study arms:
design_group_description: ACC-001(3µg) + QS21
design_group_title: ACC-001(3µg) + QS21
design_group_type: Experimental
design_group_description: ACC-001(10µg) + QS21
design_group_title: ACC-001(10µg) + QS21
design_group_type: Experimental
design_group_description: ACC-001(30µg) + QS21
design_group_title: ACC-001(30µg) + QS21
design_group_type: Experimental
Sponsor: Pfizer Inc.
Collaborators: Janssen Alzheimer Immunotherapy Research & Development LLC
Drug name mappings:
name: Vanutide cridificar
lang: EN
Clinical trial NCT07192237: Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Patients With Measurable Residual Disease Positive B-cell Acute Lymphoblastic Leukemia
Official title: Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Patients With Measurable Residual Disease Positive B-cell Acute Lymphoblastic Leukemia
Conditions: Phase 2 Study
Blinatumomab
Acute Lymphoblastic Leukemia
Summary: To find out if giving blinatumomab as injections under the skin can help to control MRD and keep the disease from coming back in participants with B-cell ALL.
Interventions:
description: Given by IV
name: Blinatumomab
type: Drug
Study arms:
design_group_description: Receiving blinatumomab as injections under the skin. The drug will be given in 35-day (5-week) treatment cycles. The injections may be given on various parts of the body, including the upper arm, thigh, stomach, and/or hips/buttocks.
design_group_title: SQ blinatumomab
design_group_type: Experimental
Sponsor: The University of Texas MD Anderson Cancer Center
Collaborators: Amgen, Inc.
Drug name mappings:
name: 贝林妥欧单抗
lang: CN
name: Blinatumomab
lang: EN
name: ブリナツモマブ（遺伝子組換え）
lang: JP
Clinical trial NCT04506463: Efficacy and Safety of MM-II for Treatment of Knee Pain in Subjects With Symptomatic Knee Osteoarthritis
Official title: A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Single-administration, Multiple-Dose Study to Demonstrate the Efficacy and Safety of MM-II for Treatment of Knee Pain in Subjects With Symptomatic Knee Osteoarthritis
Conditions: Osteoarthritis of Knee
Summary: This is a phase IIb, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of MM-II in subjects with symptomatic knee OA as compared to matching placebo.
Interventions:
description: Intra-articular injection
name: MM-II dose I
type: Drug
description: Intra-articular injection
name: MM-II dose II
type: Drug
description: Intra-articular injection
name: MM-II dose III
type: Drug
description: Intra-articular injection
name: Placebo
type: Drug
description: Intra-articular injection
name: Placebo
type: Drug
description: Intra-articular injection
name: Placebo
type: Drug
Study arms:
design_group_description: MM-II 1 ml
design_group_title: Arm A
design_group_type: Experimental
design_group_description: MM-II 3 ml
design_group_title: Arm B
design_group_type: Experimental
design_group_description: MM-II 6 ml
design_group_title: Arm C
design_group_type: Experimental
design_group_description: Placebo 1ml
design_group_title: Arm 4
design_group_type: Placebo Comparator
design_group_description: Placebo 3ml
design_group_title: Arm 5
design_group_type: Placebo Comparator
design_group_description: Placebo 6ml
design_group_title: Arm 6
design_group_type: Placebo Comparator
Sponsor: Sun Pharmaceutical Industries Ltd.
Collaborators: Moebius Medical Ltd.
Nordic Bioscience Clinical Development VII A/S
Drug name mappings:
name: MM-II
lang: EN
Clinical trial NCT01662921: Comparator Trial Using Insulin Glulisine vs. Insulin Lispro for Treatment of Gestational Diabetes
Official title: Non-inferiority Trial Comparing Insulin Glulisine to Insulin Lispro as Part of a Basal-bolus Insulin Regimen for the Treatment of Gestational Diabetes.
Conditions: Diabetes During Pregnancy
Summary: We hypothesize that insulin glulisine is non-inferior to currently proven rapid-acting insulin lispro when used in a basal/bolus regimen to treat hyperglycemia in patients with gestational diabetes mellitus.
Interventions:
description: Long acting insulin NPH dosing will be titrated weekly derived from the patients current weight and gestational age
name: NPH
other_name: Humulin N, Novolin N
type: Drug
description: Insulin lispro dosing will be titrated weekly based on the patient's average SMBG readings from each meal during the past three days
name: Insulin LISPRO
other_name: Humalog
type: Drug
description: Insulin glulisine will be titrated weekly based on the patient's average SMBG readings from each meal during the past three days
name: Insulin glulisine
other_name: Apidra
type: Drug
Study arms:
design_group_description: Patients diagnosed with diabetes during pregnancy will be randomized to long acting insulin NPH and short acting insulin lispro in a basal bolus regimen to treat post prandial hyperglycemia using a dosing schedule of 50% NPH calculated by the patients weight and gestational age and 50% lispro pending their last three SMPG average.
design_group_title: NPH and insulin lispro
design_group_type: Active Comparator
design_group_description: Patients with a diagnosis of diabetes during pregnancy will be randomized to using long acting insulin NPH and short acting insulin glulisine as treatment for post prandial hyperglycemia with a 50% NPH dosing schedule based on the weight and gestational age and 50% glulisine schedule based on their last three SMBG result average.
design_group_title: NPH and insulin glulisine
design_group_type: Active Comparator
Sponsor: Sansum Diabetes Research Institute
Collaborators: Sanofi
Drug name mappings:
name: 谷赖胰岛素
lang: CN
name: Insulin Glulisine Recombinant
lang: EN
name: インスリン グルリジン（遺伝子組換え）
lang: JP
name: 赖脯胰岛素生物类似药(Sanofi)
lang: CN
name: Insulin lispro biosimilar (Sanofi)
lang: EN
name: インスリン リスプロ BS
lang: JP
Clinical trial NCT01100268: Enhancing Attention in Adults With Compulsive Hoarding
Official title: Enhancing Attention in Adults With Compulsive Hoarding: A Pilot Study
Conditions: Hoarding Disorder
Summary: Available data suggest that compulsive hoarders have cognitive deficits, particularly with sustaining attention that might contribute their hoarding symptoms.
Interventions:
description: Subjects will start at 18mg/day; the dose will be increased in increments of 18mg per week to reach 72mg/day.
name: Methylphenidate ER
other_name: Concerta
type: Drug
Study arms:
design_group_description: Subjects will start at 18mg/day; the dose will be increased in increments of 18mg per week to reach 72mg/day.
design_group_title: Methylphenidate ER
design_group_type: Experimental
Sponsor: The New York State Psychiatric Institute
Collaborators: Hartford Hospital
Drug name mappings:
name: 盐酸哌甲酯
lang: CN
name: Methylphenidate Hydrochloride
lang: EN